Form 4: Janux Therapeutics Director Sheila Gujrathi Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Director Sheila Gujrathi reports a pro rata, in-kind distribution of Janux Therapeutics common stock.
Summary
- On February 29, 2024, Sheila Gujrathi, a director of Janux Therapeutics, Inc., reported a change in beneficial ownership of the company's common stock.
- The transaction involved the receipt of 2,986 shares of common stock through a pro rata, in-kind distribution.
- This distribution was not a purchase of securities but a receipt by ABV SPV I GP LLC, of which Ms. Gujrathi is a member.
- Following the transaction, Ms. Gujrathi's beneficial ownership of Janux Therapeutics common stock is 108,028 shares.
- The report was filed on March 4, 2024, by Maria Dobek, Attorney-in-Fact.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, indicating a neutral sentiment.
Industry Context
This filing is a routine disclosure related to changes in beneficial ownership by a company insider, which is a common occurrence in the biotechnology industry.
Stakeholder Impact
- The change in beneficial ownership may have a minor impact on shareholders, as it reflects an insider's holdings.
Key Dates
| Date | Description |
|---|---|
| 02/29/2024 | Date of transaction: pro rata, in-kind distribution of common stock. |
| 03/04/2024 | Date of filing: Form 4 filed by Maria Dobek, Attorney-in-Fact. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.